Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Pacific Biosciences of California    PACB

PACIFIC BIOSCIENCES OF CALIFORNIA

(PACB)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Pacific Biosciences of California : Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Pacific Biosciences of California, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/06/2012 | 06:20pm EDT

Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/pacb) announces that a class action lawsuit has been filed in United States District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired the common stock of Pacific Biosciences of California, Inc. ("PacBio" or the "Company") (NASDAQ: PACB) between October 27, 2010, and September 20, 2011, inclusive (the "Class Period").

For more information regarding this class action suit, please contact Ryan & Maniskas, LLP (Richard A. Maniskas, Esquire) toll-free at (877) 316-3218 or by email at rmaniskas@rmclasslaw.com or visit: www.rmclasslaw.com/cases/pacb.

The Complaint alleges that, during the Class Period, defendants failed to disclose materially adverse facts regarding the Company's operational and financial condition that were caused by significant problems with its third generation human genome sequencing technology. The Complaint further alleges that due to the Defendants' materially false and misleading statements, PacBio stock traded at artificially inflated prices throughout the Class Period.

On September 20, 2011, after the close of the market, PacBio announced it was reducing its workforce by approximately 130 employees, or approximately 28% of its total workforce. The Company thus admitted what was apparent to its analysts: its products were not selling at the rate it had projected. Moreover, with the cuts to its research and development department, the prospects for needed improvement in the Company's new and still developing technology were dim. The market reacted immediately. On this news, shares of PacBio fell $1.31 or about 24%, to close at $4.25 on heavy trading volume.

If you are a member of the class, you may, no later than February 27, 2012, request that the Court appoint you as lead plaintiff of the class. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Under certain circumstances, one or more class members may together serve as "lead plaintiff." Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. You may retain Ryan & Maniskas, LLP or other counsel of your choice, to serve as your counsel in this action.

For more information about the case or to participate online, please visit: www.rmclasslaw.com/cases/pacb or contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218, or by e-mail at rmaniskas@rmclasslaw.com. For more information about class action cases in general or to learn more about Ryan & Maniskas, LLP, please visit our website: www.rmclasslaw.com.

Ryan & Maniskas, LLP is a national shareholder litigation firm. Ryan & Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.

Ryan & Maniskas, LLP
Richard A. Maniskas, Esquire
484-588-5516
877-316-3218
rmaniskas@rmclasslaw.com
www.rmclasslaw.com/cases/pacb


© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PACIFIC BIOSCIENCES OF CAL
08/06PACIFIC BIOSCIENCES : 2Q Earnings Snapshot
AQ
08/06PACIFIC BIOSCIENCES OF CALIFORNIA : Management's Discussion and Analysis of Fina..
AQ
08/06PACIFIC BIOSCIENCES OF CALIFORNIA, I : Results of Operations and Financial Condi..
AQ
08/06PACIFIC BIOSCIENCES OF CALIFORNIA : Announces Second Quarter 2019 Financial Resu..
AQ
08/06PACIFIC BIOSCIENCES OF CALIFORNIA : Beijing-Based Annoroad Increases SMRT Sequen..
PU
07/17EXCLUSIVE : Woodford biotech stakes first off block in asset sale - source
RE
06/18PACIFIC BIOSCIENCES OF CALIFORNIA, I : Submission of Matters to a Vote of Securi..
AQ
06/18PACIFIC BIOSCIENCES OF CALIFORNIA, I : Other Events (form 8-K)
AQ
06/18CMA says Illumina-Pacific Biosciences deal could hurt competition
RE
06/18ILLUMINA : takeover of PacBio raises competition concerns
AQ
More news
Financials (USD)
Sales 2019 98,9 M
EBIT 2019 -99,4 M
Net income 2019 -100 M
Finance 2019 97,6 M
Yield 2019 -
P/E ratio 2019 -8,78x
P/E ratio 2020 -12,1x
EV / Sales2019 7,89x
EV / Sales2020 5,85x
Capitalization 878 M
Chart PACIFIC BIOSCIENCES OF CALIFORNIA
Duration : Period :
Pacific Biosciences of California Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PACIFIC BIOSCIENCES OF CAL
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 7,63  $
Last Close Price 5,74  $
Spread / Highest target 39,4%
Spread / Average Target 32,8%
Spread / Lowest Target 13,2%
EPS Revisions
Managers
NameTitle
Michael W. Hunkapiller Executive Chairman, President & CEO
Susan K. Barnes CFO, Principal Accounting Officer & Senior VP
Stephen W. Turner Chief Technology Officer
Jonas Korlach Chief Scientific Officer
William W. Ericson Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PACIFIC BIOSCIENCES OF CALIFORNIA-22.43%878
THERMO FISHER SCIENTIFIC24.90%110 607
DANAHER CORPORATION35.83%100 482
BOSTON SCIENTIFIC CORPORATION20.94%59 201
INTUITIVE SURGICAL3.95%57 377
EDWARDS LIFESCIENCES CORPORATION45.26%46 171